Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 5NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Neoplasm Metastasis 31Lung Neoplasms 25Carcinoma, Non-Small-Cell Lung 20Breast Neoplasms 19Lymphoma 18Multiple Myeloma 17Glioblastoma 17Prostatic Neoplasms 16Urinary Bladder Neoplasms 15Glioma 15Carcinoma, Renal Cell 15Melanoma 13Squamous Cell Carcinoma of Head and Neck 12Sarcoma 12Ovarian Neoplasms 12Colorectal Neoplasms 12Central Nervous System Neoplasms 12Triple Negative Breast Neoplasms 11Mouth Neoplasms 11Pancreatic Neoplasms 10Oropharyngeal Neoplasms 10Neuroblastoma 10Medulloblastoma 10Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 10Laryngeal Neoplasms 10Carcinoma, Transitional Cell 10Thyroid Neoplasms 9Fallopian Tube Neoplasms 9Ependymoma 9

Interventions

Vincristine 4Prednisone 3MLN 8237 3Doxorubicin 3Cyclophosphamide 3temsirolimus 2romidepsin 2Specimen Handling 2Sirolimus 2Rituximab 2Lenalidomide 2Lactones 2Etoposide 2Depsipeptides 2Biopsy 2veliparib 1tipifarnib 1tazemetostat 1talimogene laherparepvec 1siplizumab 1pegaspargase 1molibresib 1merphos 1liposomal doxorubicin 1entinostat 1dexamethasone acetate 1dexamethasone 21-phosphate 1belinostat 1avelumab 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, T-Cell × Magnetic Resonance Spectroscopy × Clear all
NCT05627245 2026-05-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

National Cancer Institute (NCI)

Phase 1 Active not recruiting
48 enrolled
DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡